Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.15), $0.12 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.89 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.